---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-078600"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2024-07-09T23:59:59+00:00"
generated_at: "2026-05-31T22:38:27.706560+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics completes MAD dosing for GT-02287 Phase 1; no SAEs, on track for Q4 2024 patient trial

## Summary
- Completed dosing in MAD part of Phase 1 study of GT-02287 for Parkinson's disease; no discontinuations or serious adverse events.
- GT-02287 well tolerated up to highest planned dose; 90% of adverse events mild, 10% moderate, no Grade 3+ events.
- Topline data expected mid-August after database lock; full safety and PK data to be presented at future congress.
- On track to initiate clinical trial in Parkinson's disease patients by Q4 2024.

## SEC filing metadata
- accession: 0001104659-24-078600
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2024-07-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000110465924078600/0001104659-24-078600-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000110465924078600/tm2419145d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-078600
- JSON: https://secwatch.observer/filing/0001104659-24-078600.json
- Plain text: https://secwatch.observer/filing/0001104659-24-078600.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.